COGR submitted comprehensive recommendations to the White House OSTP's request for information on "Accelerating the American Scientific Enterprise." The document...
Intellectual Property & Innovation
Covering policies and practices for federally sponsored research, Intellectual Property and Innovation ensures discoveries and creative works are effectively protected, managed, and commercialized.
Featured
Research Security Regulations: Practical Considerations for Technology Transfer Professionals
This document provides comprehensive guidance for technology transfer professionals on navigating the complex and evolving landscape of U.S. research security...
Technology Transfer in U.S. Research Universities: Dispelling Common Myths (Updated August 2022)
This document, published by COGR, systematically addresses and dispels common misconceptions about technology transfer activities within U.S. research universities...
Resources
Point of Contact
Kevin Wozniak
Director, Research Security & Intellectual Property
All Intellectual Property & Innovation Articles
COGR Responds to NSF RFC on Proposed Intellectual Property Options
COGR submitted a response to the National Science Foundation’s (NSF) request for comments regarding proposed new intellectual property (IP) frameworks for public-private partnerships, expressing concern that prescribed, inflexible IP terms could hinder successful technology transfer and commercialization of federally funded research. COGR argued that current practices, which allow for the negotiat
COGR Responds to USDOJ’s Notice of Proposed Rulemaking—Provisions Pertaining to Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons
COGR, representing over 220 U.S. research institutions, submitted comments on the Department of Justice’s proposed rule aimed at restricting access to U.S. sensitive personal and government-related data by countries of concern. COGR expresses concern that the rule’s lack of exemptions for non-federally funded, non-clinical research would severely hinder essential international public health and fo
COGR Submits Comments to NIH on Intramural Research Program Policy: Promoting Equity Through Access Planning
COGR responds to the NIH’s draft policy requiring licensees of NIH technologies to submit access plans aimed at promoting patient access, expressing support for the aim of equity but cautioning that such requirements may unintentionally complicate technology commercialization and deter potential licensees due to increased risks and uncertainties. COGR recommends that NIH focus on adjusting its own
COGR & AAU Submit Joint Comments in Response to Unlocking the Full Potential of Intellectual Property by Translating More Innovation to the Marketplace (Docket No. PTO-C-2024-004)
COGR and AAU, representing leading U.S. research universities, submitted comments to USPTO Director Kathi Vidal expressing agreement with AUTM’s positions and addressing key issues impacting university technology transfer and innovation commercialization. They voiced serious concerns about NIST's draft march-in rights framework, warning that its adoption could deter investment and harm patent lice
Higher Education Associations Comments to NIST
A coalition of leading academic associations, including AAU, APLU, AAMC, ACE, AUTM, and COGR, submitted comments opposing the National Institute of Standards and Technology's (NIST) Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights under the Bayh-Dole Act. They argue that the proposed framework introduces unnecessary ambiguity, focuses inappropriately on “reasona
COGR Submits Comments to NIST on Draft Interagency Guidance Framework for Considering the Exercise of March In Rights
COGR, representing over 200 U.S. research institutions, submitted comments urging the withdrawal of the proposed Interagency Guidance Framework for Considering the Exercise of March-In Rights under the Bayh-Dole Act. COGR argues that the Framework, particularly its consideration of product pricing as a trigger for march-in, would undermine successful technology transfer practices, deter industry p
COGR Joins a Multi-Association Extension Request to NIST for the RFI Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No.: 230831-0207)
The letter, sent by major associations representing research universities and medical colleges, requests a 90-day extension to the public comment period on the National Institute of Standards and Technology's draft interagency guidance framework regarding the exercise of march-in rights under the Bayh-Dole Act. The organizations express concern that the proposed changes significantly depart from l
COGR Joins C4IP in Urging the Biden Administration to Oppose the Proposed WTO IP Waiver for Covid-19 Therapeutics and Diagnostics
The letter, dated December 4, 2023, is addressed to President Joseph R. Biden by the Council for Innovation Promotion, a bipartisan group comprised of former senior government officials, university technology transfer experts, and leaders from trade and health sectors. The signatories urge President Biden to oppose the World Trade Organization's proposed waiver of intellectual property (IP) r
COGR Submits Joint Association Response to OMB on Comment Request; iEdison System
The letter, submitted by COGR and other higher education associations, expresses strong support for the continued redesign, expansion, and harmonization of the iEdison invention reporting system across all federal agencies, as outlined in OMB Control No. 0693-0090. The associations highlight the benefits of uniform reporting requirements under the Bayh-Dole Act, including reduced compliance burden
COGR, AAU, and AUTM Submit Joint Association Letter on COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities
The letter, submitted jointly by the Association of American Universities (AAU), the Council on Government Relations (COGR), and AUTM, addresses the U.S. International Trade Commission in relation to Investigation No. 332-596, focusing on COVID-19 diagnostics, therapeutics, and the possible expansion of the TRIPS Agreement waiver. The associations, representing leading American research universiti
